Brief: YS Biopharma Phase 3 Clinical Trial Will Evaluate Immunogenicity Of Co's Pika Rabies Vaccine
16/05/2023 12:11
May 16 (Reuters) - YS Biopharma Co Ltd YS.O :
* YS BIOPHARMA'S PIKA RABIES VACCINE RECEIVES PHASE 3
CLINICAL
TRIAL APPROVAL IN PAKISTAN
* YS BIOPHARMA - PHASE 3 CLINICAL TRIAL WILL EVALUATE SAFETY
AND
IMMUNOGENICITY OF CO'S PIKA RABIES VACCINE IN PREVENTING RABIES
INFECTION
Source text for Eikon: ID:nPn9HCsMja
Further company coverage: YS.O
Recent news on LakeShore Biopharma Co
See all newsBrief: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
Brief: LakeShore Biopharma Appoints Advisors to Special Committee Reviewing Takeover Bid
Brief: Lakeshore Biopharma Announces Receipt Of A Preliminary Non-Binding Proposal To Acquire The Company
Brief: Lakeshore Biopharma Expects 2026 Revenue To Be Between RMB550 Million And RMB650 Million
Brief: Lakeshore Biopharma Announces Us$15 Million Private Placement Financing